Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T21:41:32.896Z.
Calculation as of: 2026-10-06T21:41:32.896Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 1f516b86ce6f8a32b007838909cf85d374f635633f340bc308fa792387434ce1
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Market Cap
$266.59M
EBITDA Yield
N/A
TTM Avg
1.92%
3Y Avg
1.92%
5Y Avg
1.92%
Market Cap
$265.78M
EBITDA Yield
N/A
TTM Avg
10.04%
3Y Avg
10.04%
5Y Avg
9.67%
Market Cap
$270.80M
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$262.92M
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$271.81M
EBITDA Yield
N/A
TTM Avg
53.15%
3Y Avg
20.52%
5Y Avg
13.83%
Market Cap
$261.43M
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Fate Therapeutics, Inc. (FATE) | $266.92M | N/A | N/A | N/A | N/A |
| SAB Biotherapeutics, Inc. (SABS)vs › | $266.59M | N/A | 1.92% | 1.92% | 1.92% |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $265.78M | N/A | 10.04% | 10.04% | 9.67% |
| Scribe Therapeutics Inc. (SCTX)vs › | $264.25M | N/A | N/A | N/A | N/A |
| Rocket Pharmaceuticals, Inc. (RCKT)vs › | $270.80M | N/A | N/A | N/A | N/A |
| TriSalus Life Sciences, Inc. (TLSI)vs › | $262.92M | N/A | N/A | N/A | N/A |
| Vanda Pharmaceuticals Inc. (VNDA)vs › | $271.81M | N/A | 53.15% | 20.52% | 13.83% |
| Inhibikase Therapeutics, Inc. (IKT)vs › | $261.43M | N/A | N/A | N/A | N/A |
| X4 Pharmaceuticals, Inc. (XFOR)vs › | $261.27M | N/A | N/A | N/A | N/A |
| OraSure Technologies, Inc. (OSUR)vs › | $259.56M | N/A | 55.26% | 33.09% | 19.40% |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
